Adial Pharmaceuticals
ADIL
23 hedge funds and large institutions have $3.61M invested in Adial Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
15% more funds holding
Funds holding: 20 → 23 (+3)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
34% less capital invested
Capital invested by funds: $5.5M → $3.61M (-$1.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$104K |
| 2 |
BlackRock
New York
|
+$100K |
| 3 |
Goldman Sachs
New York
|
+$61K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$124K |
| 2 |
NP
NorthRock Partners
Minneapolis,
Minnesota
|
-$43K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.8K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$3.94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.97K |
ADIL Hedge Fund Activity: Q4 2021 in Review
23 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2021, worth a combined $3.61M — down 34% from $5.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ADIL positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $104K. The largest seller was Morgan Stanley, cutting an estimated $124K.
- 23 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2021, up from 20 in Q3 2021.
- Funds reported $3.61M of Adial Pharmaceuticals stock for Q4 2021, down 34% quarter-over-quarter.
- 4 funds opened new Adial Pharmaceuticals positions in Q4 2021 and 1 closed out, a net change of +3 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2021 was Geode Capital Management, an estimated $104K added.
- The largest Adial Pharmaceuticals seller in Q4 2021 was Morgan Stanley, an estimated $124K sold.
Based on aggregated 13F filings for Q4 2021.